Sensitive Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift Biosciences' SARS-CoV-2 Multiplex Amplicon Sequencing Panel

Amin Addetia,[a] Michelle J. Lin,[a] Vikas Peddu,[a] Pavitra Roychoudhury,[a,b] Keith R. Jerome,[a,b] Alexander L. Greninger[a,b]

[a]Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA
[b]Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Whole-genome sequencing (WGS) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a better understanding of the virus's origin, transmission, and evolution (1–6). Multiplex amplicon sequencing for viral WGS is a preferred approach to library preparation since it is simple, sensitive, cost-effective, and scalable (7, 8). However, balancing multiplexed primers to achieve high sensitivity and even coverage can be difficult (8), and superlative analytical sensitivity is not assured. Here, we evaluated the Swift Biosciences' single-tube SARS-CoV-2 multiplex amplicon sequencing panel for the recovery of genomes from low-viral-load samples (threshold cycle [C_T] > 26 on a Hologic Panther Fusion system).

This work was approved by the University of Washington Institutional Review Board (proposal no. STUDY00000408). Libraries were constructed from double-stranded cDNA using Swift Biosciences' Normalase amplicon SARS-CoV-2 panel. The resulting libraries were sequenced on 2× 300-bp MiSeq runs, and a median of 605,654 reads were obtained for each library. Genomes were assembled with a custom pipeline, TAYLOR (https://github.com/greninger-lab/covid_swift_pipeline). Briefly, sequence reads were trimmed using Trimmomatic v0.38, aligned to the Wuhan-Hu-1 genome (NCBI accession no. NC_045512.2) using BBMap v38.70 (https://sourceforge.net/projects/bbmap/), and trimmed of PCR primers using Primerclip (https://github.com/swiftbiosciences/primerclip). Consensus genomes were called bcftools v1.9.

The 61 samples sequenced had C_T values ranging from 26.04 to 37.93. We recovered genomes from all samples with a C_T of ≤32.16 and from a sample with a C_T value of 36.77, equivalent to approximately 4.24 copies input (Fig. 1A) (9–11). For samples with a C_T value between 32.01 and 34.00, we recovered genomes from 8/10 (80%) of the samples, and for samples with a C_T value between 34.01 and 36.00, we recovered genomes from 4/10 (40%) of the samples. While we recovered genomes from just 3 of the samples with a C_T value between 36.01 and 38.00, we were able to recover partial genomes for the other 7 samples (median genome covered, 36.0%; range, 4.9 to 73.7%).

The libraries produced with the Swift SARS-CoV-2 amplicon panel were highly enriched for SARS-CoV-2 reads. Samples with C_T values ranging from 26.01 to 32.00 had a median on-target percentage of 98.5% (range, 93.1 to 99.0%) after removal of reads attributed to primer dimer formation (Fig. 1B). Among samples with C_T values from 32.01 to 38.00, the median on-target percentage was 92.4% (range, 16.5 to 98.7) (Fig. 1B).

We also assessed the coverage distribution from samples with an average depth of >100×. The coverage across the genome for the 41 samples analyzed was highly even (Pielou's evenness, 0.988) (Fig. 1C). To assess reproducibility, we performed 8 separate library preparations on a single sample. All 8 preparations yielded identical consensus

Address correspondence to Alexander L. Greninger, agrening@uw.edu.

FIG 1 Evaluation of the Swift Biosciences' SARS-CoV-2 multiplex amplicon sequencing panel. (A) Complete genomes were recovered from all samples with a C_T value of ≤32.16 and a C_T value as high as 36.77. Samples for which complete genomes (>95% genome coverage) were recovered are highlighted in purple. Partial genomes are highlighted in gold. (B) SARS-CoV-2 sequences were highly enriched in the sequencing libraries as measured by the percentage of reads mapping to the reference genome for SARS-CoV-2 (NCBI accession no. NC_045512.2). Complete genomes were recovered for samples highlighted in purple, while partial genomes were recovered for those highlighted in gold. (C) The genome coverage between nucleotides 201 and 29741 of the SARS-CoV-2 reference genome is even. The 5th and 95th percentiles of coverage at each position across the 41 samples with a mean depth of >100× are plotted in purple. A 250-nucleotide window moving average is represented in gold. (D) The 46 SARS-CoV-2 samples with complete genomes belong to both major SARS-CoV-2 lineages. A phylogenetic tree with the 46 SARS-CoV-2 genomes recovered in this report and 109 other global strains was constructed with FastTree version 2.1.1. Strains belonging to lineage A are highlighted in purple, while those belonging to lineage B are highlighted in gold. Those genomes sequenced in this report are circled in black. SNV, single nucleotide variation.

sequences, demonstrating the high reproducibility of the Swift SARS-CoV-2 amplicon panel.

Lastly, we performed a phylogenetic analysis of the 46 strains with complete genomes and 109 randomly selected global SARS-CoV-2 strains. The 46 strains belonged to both major lineages defined by pangolin (https://github.com/cov-lineages/pangolin) (12) and reflected the genomic diversity currently circulating in the SARS-CoV-2 population (Fig. 1D).

In summary, the Swift SARS-CoV-2 amplicon panel is a simple, highly sensitive approach for recovering SARS-CoV-2 genomes. The panel has allowed for the study of genomic rearrangements and mutations that are uniquely associated with low-viral-load samples (13, 14).

Data availability. Sequencing data are available under NCBI BioProject no. PRJNA610428 (Table 1). Code for assembling consensus FASTA genomes from FASTQ files is also available online (https://github.com/greninger-lab/covid_swift_pipeline).

TABLE 1 Assembly and sequencing read accession numbers for strains sequenced in this study[a]

Strain	GISAID accession no.	SRA accession no.
WA-UW-4544	NA	SRR12473512
WA-UW-4545	EPI_ISL_460621	SRR11939565
ID-UW-4550	EPI_ISL_460622	SRR11939564
WA-UW-4554	NA	SRR12473511
WA-UW-4555	EPI_ISL_460623	SRR11939553
WA-UW-4562	EPI_ISL_460624	SRR11939542
WA-UW-4563	EPI_ISL_515271	SRR11939540
WA-UW-4569	EPI_ISL_515272	SRR11939539
WA-UW-4570	EPI_ISL_460625	SRR11939538
WA-UW-4572	EPI_ISL_497872	SRR11939537
WA-UW-4581	EPI_ISL_515273	SRR11939536
WA-UW-4585	EPI_ISL_515274	SRR11939535
WA-UW-4588	EPI_ISL_460626	SRR11939563
WA-UW-4589	EPI_ISL_515275	SRR11939562
WA-UW-4591	EPI_ISL_460627	SRR11939561
WA-UW-4592	EPI_ISL_515276	SRR11939560
ID-UW-4597	EPI_ISL_460628	SRR11939559
WA-UW-4599	EPI_ISL_515277	SRR11939558
ID-UW-4600	EPI_ISL_460629	SRR11939557
ID-UW-4601	EPI_ISL_515270	SRR11939556
WA-UW-4603	EPI_ISL_515278	SRR11939555
WA-UW-4607	EPI_ISL_513632	SRR12515115
WA-UW-4608	EPI_ISL_515279	SRR11939554
WA-UW-4610	EPI_ISL_515286	SRR12515114
WA-UW-4614	EPI_ISL_515280	SRR11939552
WA-UW-4615	EPI_ISL_515281	SRR11939551
WA-UW-4616	EPI_ISL_515282	SRR11939550
WA-UW-4618	EPI_ISL_515283	SRR11939549
WA-UW-4619	EPI_ISL_460630	SRR11939548
WA-UW-4620	EPI_ISL_515284	SRR11939547
WA-UW-4623	EPI_ISL_515285	SRR11939546
WA-UW-4627	EPI_ISL_513633	SRR12515113
WA-UW-4632	EPI_ISL_460631	SRR11939545
WA-UW-4633	EPI_ISL_460632	SRR11939544
WA-UW-4636	NA	SRR12473505
WA-UW-4641	NA	SRR12473504
WA-UW-4643	EPI_ISL_460633	SRR11939543
WA-UW-4646	EPI_ISL_460634	SRR11939541
WA-UW-4648	NA	SRR12473503
WA-UW-4657	EPI_ISL_461399	SRR11940010
WA-UW-4660	EPI_ISL_513634	SRR11940009
WA-UW-4663	EPI_ISL_461400	SRR11939943
WA-UW-4664	EPI_ISL_513635	SRR11939932
WA-UW-4665	NA	SRR12473502
WA-UW-4684	EPI_ISL_461401	SRR11939921
WA-UW-4687	NA	SRR12473501
WA-UW-4698	EPI_ISL_461402	SRR11939974
WA-UW-4731	EPI_ISL_513636	SRR12515112
WA-UW-4735	NA	SRR12473500
WA-UW-4738	NA	SRR12473499
WA-UW-4750	NA	SRR12473498
WA-UW-4758	EPI_ISL_513637	SRR11939963
WA-UW-4761	NA	SRR12473510
WA-UW-4765	EPI_ISL_461403	SRR11939952
WA-UW-4881	NA	SRR12473509
WA-UW-4884	NA	SRR12473508
WA-UW-4888	NA	SRR12473507
WA-UW-4898	EPI_ISL_513638	SRR12515111
WA-UW-4903	NA	SRR12473506
WA-UW-4917	EPI_ISL_461404	SRR11939996
WA-UW-4931	EPI_ISL_461405	SRR11939985

[a]Samples without a GISAID accession number were not considered complete genomes. NA, not applicable.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

REFERENCES

1. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. 2020. The proximal origin of SARS-CoV-2. Nat Med 26:450–452. https://doi.org/10.1038/s41591-020-0820-9.

2. Deng X, Gu W, Federman S, Du Plessis L, Pybus OG, Faria NR, Wang C, Yu G, Bushnell B, Pan C-Y, Guevara H, Sotomayor-Gonzalez A, Zorn K, Gopez A, Servellita V, Hsu E, Miller S, Bedford T, Greninger AL, Roychoudhury P, Starita LM, Famulare M, Chu HY, Shendure J, Jerome KR, Anderson C, Gangavarapu K, Zeller M, Spencer E, Andersen KG, MacCannell D, Paden CR, Li Y, Zhang J, Tong S, Armstrong G, Morrow S, Willis M, Matyas BT, Mase S, Kasirye O, Park M, Masinde G, Chan C, Yu AT, Chai SJ, Villarino E, Bonin B, Wadford DA, Chiu CY. 2020. Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California. Science 369:582–587. https://doi.org/10.1126/science.abb9263.

3. Fauver JR, Petrone ME, Hodcroft EB, Shioda K, Ehrlich HY, Watts AG, Vogels CBF, Brito AF, Alpert T, Muyombwe A, Razeq J, Downing R, Cheemarla NR, Wyllie AL, Kalinich CC, Ott IM, Quick J, Loman NJ, Neugebauer KM, Greninger AL, Jerome KR, Roychoudhury P, Xie H, Shrestha L, Huang M-L, Pitzer VE, Iwasaki A, Omer SB, Khan K, Bogoch II, Martinello RA, Foxman EF, Landry ML, Neher RA, Ko AI, Grubaugh ND. 2020. Coast-to-coast spread of SARS-CoV-2 during the early epidemic in the United States. Cell 181:990–996.E5. https://doi.org/10.1016/j.cell.2020.04.021.

4. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J, Lu J. 2020. On the origin and continuing evolution of SARS-CoV-2. Natl Sci Rev 7:1012–1023. https://doi.org/10.1093/nsr/nwaa036.

5. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM, Freeman TM, de Silva TI, McDanal C, Perez LG, Tang H, Moon-Walker A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC, Angyal A, Brown RL, Carrilero L, Green LR, Groves DC, Johnson KJ, Keeley AJ, Lindsey BB, Parsons PJ, Raza M, Rowland-Jones S, Smith N, Tucker RM, Wang D, Wyles MD. 2020. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell 182:812–827.E19. https://doi.org/10.1016/j.cell.2020.06.043.

6. Bedford T, Greninger AL, Roychoudhury P, Starita LM, Famulare M, Huang M-L, Nalla A, Pepper G, Reinhardt A, Xie H, Shrestha L, Nguyen TN, Adler A, Brandstetter E, Cho S, Giroux D, Han PD, Fay K, Frazar CD, Ilcisin M, Lacombe K, Lee J, Kiavand A, Richardson M, Sibley TR, Truong M, Wolf CR, Nickerson DA, Rieder MJ, Englund JA, Hadfield J, Hodcroft EB, Huddleston J, Moncla LH, Müller NF, Neher RA, Deng X, Gu W, Federman S, Chiu C, Duchin JS, Gautom R, Melly G, Hiatt B, Dykema P, Lindquist S, Queen K, Tao Y, Uehara A, Tong S, MacCannell D, Armstrong GL, Seattle Flu Study Investigators, et al. 2020. Cryptic transmission of SARS-CoV-2 in Washington state. Science. https://doi.org/10.1126/science.abc0523.

7. Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, Choi JH, Lapointe H, Kamelian K, Smith AD, Prystajecky N, Goodfellow I, Wilson SJ, Harrigan R, Snutch TP, Loman NJ, Quick J. 2020. Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv https://doi.org/10.1101/2020.09.04.283077.

8. Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M. 2020. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS One 15:e0239403. https://doi.org/10.1371/journal.pone.0239403.

9. Lieberman JA, Pepper G, Naccache SN, Huang M-L, Jerome KR, Greninger AL. 2020. Comparison of commercially available and laboratory-developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 58:e00821-20. https://doi.org/10.1128/JCM.00821-20.

10. Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, Wei Y, Zhu H, Jerome KR, Greninger AL. 2020. Comparative performance of SARS-CoV-2 detection assays using seven different primer-probe sets and one assay kit. J Clin Microbiol 58:e00557-20. https://doi.org/10.1128/JCM.00557-20.

11. Perchetti GA, Nalla AK, Huang M-L, Zhu H, Wei Y, Stensland L, Loprieno MA, Jerome KR, Greninger AL. 2020. Validation of SARS-CoV-2 detection across multiple specimen types. J Clin Virol 128:104438. https://doi.org/10.1016/j.jcv.2020.104438.

12. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, Du Plessis L, Pybus OG. 15 July 2020. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol https://doi.org/10.1038/s41564-020-0770-5.

13. Addetia A, Xie H, Roychoudhury P, Shrestha L, Loprieno M, Huang M-L, Jerome KR, Greninger AL. 2020. Identification of multiple large deletions in ORF7a resulting in in-frame gene fusions in clinical SARS-CoV-2 isolates. J Clin Virol 129:104523. https://doi.org/10.1016/j.jcv.2020.104523.

14. Addetia A, Lieberman NAP, Phung Q, Xie H, Roychoudhury P, Shrestha L, Loprieno M, Huang M-L, Jerome KR, Greninger AL. 2020. SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98. bioRxiv https://www.biorxiv.org/content/10.1101/2020.08.03.234559v1.full.